Ocugen Nears a Pivotal Week as Court Date and Earnings Collide With Regulatory Ambitions

Ocugen's pivotal week includes Q1 earnings, a Delaware court ruling on share structure, and progress on OCU400 gene therapy targeting 99% of retinitis pigmentosa patients.

The first week of May is shaping up to be a defining moment for Ocugen. On May 5, the biotech group will release its quarterly earnings and provide a pipeline update, followed the next day by a critical hearing before the Chancery Court in Delaware. The court case centers on the company’s capital structure — specifically, the retroactive validation of a charter amendment that significantly expanded its authorized common share count. A favorable ruling would resolve a long-running dispute over voting rights tied to certain preferred shares, giving investors the clarity they need to assess future financing moves.

OCU400 Takes Center Stage in the Regulatory Push

Operationally, Ocugen is preparing to transition from a clinical-stage developer to a commercial entity. The company plans to launch a rolling Biologics License Application (BLA) for its lead candidate, OCU400, in the second half of 2026 — specifically targeting the third quarter. That filing will be backed by topline data from the Phase 3 liMeliGhT study, which has already fully enrolled 140 patients with retinitis pigmentosa. Results are expected in the first quarter of 2027, and they are designed to directly support the BLA submission.

OCU400 stands apart from existing therapies. The only approved gene therapy for retinitis pigmentosa targets a single genetic mutation affecting just one to two percent of patients. Ocugen’s candidate uses a modifier approach through NR2E3 and is designed to address 98 to 99 percent of all RP patients with a single treatment.

Pipeline Progress and Commercial Steps

Beyond OCU400, the company is making headway across its pipeline. Positive Phase 2 data for OCU410 in geographic atrophy have been reported, and enrollment in the Phase 2/3 GARDian3 study for OCU410ST in Stargardt disease is advancing rapidly. At the optimal dose, OCU410 reduced lesion growth by roughly 30 percent. A pivotal follow-up study is slated to begin in late summer. Dosing in the clinical trial for OCU410ST is already complete, with initial meaningful results expected in spring 2027.

On the commercial front, Ocugen took an early step in 2025 by signing a licensing agreement with Kwangdong Pharmaceutical for South Korea. The deal grants exclusive Korean rights to OCU400 in exchange for upfront payments, milestone payments, and royalties.

Financing and Cash Position

The company’s financial runway appears secure for now. Management says existing cash will last into the final quarter of this year. Recent funding includes a $22.5 million underwritten offering from January 2026 and $15 million from warrant exercises. Executive compensation is heavily performance-based, with stock options and performance stock units tied to total shareholder return and clinical milestones.

Stock in a Holding Pattern

The market has taken a cautious stance. Ocugen shares currently trade around €1.46, well below the March high but still up roughly 128 percent over the past twelve months. Over the last 30 days, the stock has lost nearly eight percent and sits below its 50-day moving average. On a yearly basis, the share price has more than doubled from the May 2025 low, though it remains roughly 35 percent below the 52-week high.

The annual shareholder meeting is scheduled for June 11, 2026, as a virtual event. Shareholders on record as of April 20, 2026, are eligible to vote. The agenda includes the election of two directors, ratification of PwC as auditor, and a vote on executive compensation policy.

The coming days will test whether Ocugen can deliver on its ambitious timeline. The earnings call on May 5 must convince investors that the regulatory roadmap is on track, while the court ruling the following day will determine the company’s flexibility in future capital-raising efforts. A win in Delaware would remove a major overhang, potentially unlocking a clearer path forward for the stock.